TEVA's CGRP migraine drug is decent, but they screwed up by not acquiring a PVR for it. So I'm assuming they'll be second to market after AMGN - still should be a good drug for them.
The time to buy them might be after they cut their dividend.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.